Literature DB >> 7568628

Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats.

R L Barrett1, J L Wiley, R L Balster, B R Martin.   

Abstract

While many previous studies have shown that a variety of cannabinoids substitute and cross-substitute for delta 9-tetrahydrocannabinol (THC) in drug discrimination procedures, few have systematically examined potential THC-like effects of non-cannabinoid compounds. The purpose of the present study was to delineate further the pharmacological specificity of THC discrimination. Rats were trained to discriminate THC (3.0 mg/kg) from vehicle. Following determination of a dose-effect curve with THC, substitution tests with selected compounds from a variety of pharmacological classes, including l-phenylisopropyl adenosine, dizocilpine, dextromethorphan, clozapine, buspirone, MDL 72222, muscimol, midazolam and chlordiazepoxide, were performed. Whereas THC produced full dose-dependent substitution, substitution tests with non-cannabinoid drugs resulted in less than chance (50%) levels of responding on the THC-appropriate lever, with the exception of (+)-MDMA (2.5 mg/kg, 50%) and diazepam (3.0 mg/kg, 67%). These results are consistent with those of previous studies and suggest that the discriminative stimulus effects of THC exhibit pharmacological specificity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568628     DOI: 10.1007/BF02245942

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids.

Authors:  R G Pertwee; A P Wickens
Journal:  Neuropharmacology       Date:  1991-03       Impact factor: 5.250

2.  Antianxiety effect of cannabis: involvement of central benzodiazepine receptors.

Authors:  B B Sethi; J K Trivedi; P Kumar; A Gulati; A K Agarwal; N Sethi
Journal:  Biol Psychiatry       Date:  1986-01       Impact factor: 13.382

3.  The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol.

Authors:  D J Mokler; B D Nelson; L S Harris; J A Rosecrans
Journal:  Life Sci       Date:  1986-04-28       Impact factor: 5.037

4.  Pharmacological characterization of cannabinoids in the elevated plus maze.

Authors:  E S Onaivi; M R Green; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1990-06       Impact factor: 4.030

5.  Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam.

Authors:  T H Kelly; R W Foltin; C S Emurian; M W Fischman
Journal:  J Anal Toxicol       Date:  1993-09       Impact factor: 3.367

6.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

Authors:  D R Compton; L H Gold; S J Ward; R L Balster; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

7.  A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys.

Authors:  L H Gold; R L Balster; R L Barrett; D T Britt; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

8.  Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice.

Authors:  R G Pertwee; S G Greentree; P A Swift
Journal:  Neuropharmacology       Date:  1988-12       Impact factor: 5.250

9.  Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide.

Authors:  R G Pertwee; S G Greentree
Journal:  Neuropharmacology       Date:  1988-05       Impact factor: 5.250

10.  Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.

Authors:  J L Wiley; R L Barrett; J Lowe; R L Balster; B R Martin
Journal:  Neuropharmacology       Date:  1995-06       Impact factor: 5.250

View more
  23 in total

1.  Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 2.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

3.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

Review 4.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

5.  Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.

Authors:  Jenny L Wiley; D Matthew Walentiny; Robert E Vann; Cassandra Y Baskfield
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

6.  Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2014-07-29       Impact factor: 4.492

7.  Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Megan Grabenauer; Katherine N Moore; John W Huffman; Brian F Thomas
Journal:  Neuropharmacology       Date:  2016-07-20       Impact factor: 5.250

8.  Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats.

Authors:  Daniel G Barrus; Timothy W Lefever; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2018-05-03       Impact factor: 5.250

9.  Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-03-16       Impact factor: 4.030

10.  In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.

Authors:  Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas
Journal:  Pharmacol Biochem Behav       Date:  2020-04-02       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.